Johnson & Johnson (J&J) had net income of US$ 3.52 billion in the fourth quarter of 2022, an amount 25.7% lower than the gain of US$ 4.74 billion recorded in the same period of the previous year, according to a balance sheet published this Tuesday (24).
With adjustments, the American multinational in the pharmaceutical sector secured earnings per share of US$ 2.35 between October and December, surpassing the consensus of analysts consulted by FactSet, of US$ 2.23.
J&J’s revenue fell 4.4% year-on-year in the last quarter to $23.7 billion, slightly below the FactSet consensus of $23.9 billion.
In the wake of the balance sheet, the company’s stock jumped 2.5% in pre-market business in New York at 8:47 am (Brasília time).
J&J also revealed that it expects to earn adjusted earnings per share of $10.45 to $10.65 in 2023, and generate revenues of $96.9 billion to $97.9 billion.
Source: CNN Brasil
I am an experienced journalist, writer, and editor with a passion for finance and business news. I have been working in the journalism field for over 6 years, covering a variety of topics from finance to technology. As an author at World Stock Market, I specialize in finance business-related topics.
